Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazosentan for Reversing Cerebral Vasospasm in aSAH
NCT02560532Phase 2Completed
- Sponsor
- Idorsia
- Start
- Mar 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of clazosentan in cerebral vasospasm, sponsored by Idorsia. Primary endpoint: Successful reversal of global cerebral vasospasm 3 hours post-study drug initiation. Started Mar 2016; status: completed.
02
Drugs
clazosentan
03
Conditions
cerebral vasospasm
Beyond the preview
Go deeper on NCT02560532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560532.